Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024

The non-alcoholic steatohepatitis (nash) market size has grown exponentially in recent years. It will grow from $3.33 billion in 2023 to $4.54 billion in 2024 at a compound annual growth rate (CAGR) of 36.3%. </bThe expansion observed in the previous period can be ascribed to the increasing incidence of non-alcoholic steatohepatitis (NASH), the surge in obesity rates, heightened awareness and diagnostic efforts, changes in lifestyle and dietary habits, and advancements in healthcare infrastructure development.

The non-alcoholic steatohepatitis (nash) market size is expected to see exponential growth in the next few years. It will grow to $14.53 billion in 2028 at a compound annual growth rate (CAGR) of 33.7%. Anticipated growth in the forecast period is driven by advancements in NASH drug development, increased screening initiatives, higher healthcare spending, collaborative research, and government support. Key trends include a focus on lifestyle interventions, enhanced collaboration in clinical research, regulatory advancements, and the integration of artificial intelligence in diagnosis and monitoring.

The escalating prevalence of obesity is fueling the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by abnormal or excessive fat accumulation, poses significant health concerns, representing body weight that exceeds healthy or standard levels for a person of a given height. The increasing incidence of non-alcoholic fatty liver disease, driven by the obesity pandemic, positions NASH as a potential leading cause of severe liver disease in the coming decades. This heightened risk underscores the growing need for NASH treatment and related pharmaceuticals. As reported in the COVID-19 and Obesity, The 2021 Atlas published by the World Obesity Federation in April 2021, over 60% of the US population was recorded as overweight. Furthermore, the report projected an expected increase in obesity rates to 44.2% for males and 44.4% for females in the US population by 2025. This data highlights the alarming rise in obesity cases, reinforcing the anticipated growth trajectory of the Non-Alcoholic Steatohepatitis (NASH) market as a consequence of the obesity epidemic.

The rising demographic of the geriatric population is a key driver fueling the demand for the non-alcoholic steatohepatitis (NASH) market. The geriatric population, representing individuals aged 65 and older, exhibits specific healthcare needs associated with aging. The ongoing development and advancements in treatments within the NASH market play a crucial role in enhancing overall health outcomes for the elderly, addressing a prevalent liver-related condition prevalent in aging individuals. As indicated by the World Health Organization in October 2022, the global elderly population is anticipated to witness a significant increase, with 1 in 6 individuals being 60 or older by 2030 and an estimated 2.1 billion elderly people by 2050. This demographic shift underscores the imperative role of the increasing geriatric population in driving the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Technological advancement is a pivotal trend gaining traction in the non-alcoholic steatohepatitis (NASH) market, with major players in the industry actively pursuing technological innovations to sustain their positions. An illustrative example is the initiative undertaken by GENFIT Inc., a France-based biotechnology company, in May 2021. GENFIT launched NASHnext, a novel non-invasive test designed for diagnosing non-alcoholic steatohepatitis (NASH). NASHnext leverages the power of NIS4TM, an exclusive screening technology developed by GENFIT, utilizing a groundbreaking blood-based molecular biomarker test for the detection of NASH and severe fibrosis. This advanced diagnostic test is currently available exclusively in the United States and Canada through Labcorp, a prominent global life sciences company. By integrating cutting-edge technology into diagnostic solutions, companies such as GENFIT aim to enhance the accuracy and efficiency of NASH diagnosis, reflecting the broader trend of technological innovation within the non-alcoholic steatohepatitis market.

Prominent companies in the non-alcoholic steatohepatitis (NASH) market are actively engaged in the development of innovative products, exemplified by a focus on a thyroid hormone receptor (THR)-ß selective agonist. This innovative therapeutic approach is designed to target fundamental underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor, a pivotal protein regulating gene expression upon binding with thyroid hormones, plays a crucial role in various physiological processes. A case in point is Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company, which completed the submission of a New Drug Application in July 2023, seeking accelerated approval for Resmetirom in the treatment of NASH with liver fibrosis. Resmetirom, offering once-daily oral therapy and liver-directed action, specifically targets hepatic steatosis, inflammation, and hepatocellular injury associated with NASH and liver fibrosis. Notably designated as a Breakthrough Therapy by the FDA, and supported by a comprehensive clinical development program, including Phase 3 trials, Resmetirom showcases significant potential to address unmet medical needs. This advancement positions it as a promising addition to the evolving treatment landscape for NASH with liver fibrosis.

In July 2022, Advanz Pharma Corp. Limited, a prominent UK-based pharmaceutical company, successfully acquired Intercept Pharmaceuticals Inc for an undisclosed sum. This strategic acquisition is designed to solidify Advanz Pharma's position in the rare disease treatment sector, specifically through the addition of the ex-U.S. rights to Ocaliva (obeticholic acid), an orphan medicine used for treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc., a distinguished U.S.-based biopharmaceutical company specializing in innovative therapies for progressive non-viral liver disorders, aligns well with Advanz Pharma's strategic goals in expanding its pharmaceutical portfolio.

Major companies operating in the non-alcoholic steatohepatitis (nash) market report are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Cempra Pharmaceuticals Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Vivus LLC, Arisaph Pharmaceuticals Inc., Galectin Therapeutics Inc., Raptor Pharmaceutical Inc., VERVA Technologies Pvt. Ltd., Viking Therapeutics, Conatus Pharmaceuticals Inc., One Way Liver S.L., BioPredictive S.A.S., Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2023. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Non-alcoholic steatohepatitis (NASH) is classified into solid and liquid forms. Solid variants are predominantly produced in crystalline forms, sold in tablet formats for oral consumption, owing to their superior purity and durability. Products in this category, such as vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others, target various health conditions including hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. These products are distributed through hospital pharmacies, retail pharmacies, and online providers, encompassing both oral and parenteral applications.

The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.